Journal of Medical Diagnostic Methods
ISSN: 2168-9784
OPEN ACCESS Freely available online
Opinion

Recent Medical Advancements in Diabetic Retinal Disease Treatment

Gloria Simmons*
Editorial office, Journal of Medical Diagnostic Methods, Barcelona, Spain

OPINION

Diabetic retinal disease is a primary cause of preventable blindness and one of the most common consequences of Diabetes Mellitus (DM). Glycemic control, intravitreal, and laser therapy are the mainstays of treatment. Intravitreal therapy, on the other hand, often necessitates repeated hospital visits, and some patients do not see a meaningful improvement in eyesight. Novel and long-acting medicines targeting a variety of pathways are needed, however there is currently inadequate evidence to support appropriate treatment combinations. The discovery of therapeutic medicines that target not just visible microvascular illness and metabolic derangements, but also inflammation and accelerated retinal neurodegeneration is being driven by a better knowledge of the molecular mechanisms involved in pathogenesis. This review outlines existing and emerging treatments for diabetic retinal disorders, as well as providing an outlook on how to manage this critical condition in the future. Diabetic retinal problems encompass a wide range of glycemic retinal damage, including microvascular Diabetic Retinopathy (DR) with neovascularization and retinal detachment, Diabetic Macular Edoema (DME), and rapid neurocellular degeneration. DR is the most frequent microvascular consequence of diabetes mellitus (DM) and a primary cause of preventable blindness in the developed world, affecting over 95 million people. Diabetes is becoming more common, with 592 million people expected to be affected by 2035. The Diabetes Management and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Trial (UKPDS) for type 1 (T1DM) and type 2 (T2DM) diabetes indicated that strict blood glucose control can delay the onset and progression of DR in both types of diabetes. However, the growing number of patients underscores the need for additional advancements in DRD treatment in order to reduce ocular morbidity. DR is a microangiopathy characterised by retinal capillary blockage and leaking. Chronic hyperglycemia, basal membrane thickening, pericyte death, and hemodynamic alterations are all part of the pathogenesis. Oxidative stress, increased production of Vascular Endothelial Growth Factor (VEGF), and Insulin-Like Growth Factor-1 are all important causes (IGF-1). The main risk factors for DR include hyperglycemia, dyslipidemia, and hypertension, in addition to hyperglycemia. However, when compared to normal standards, improved blood pressure regulation has little effect on DR progression. Non-Alcoholic Fatty Liver Disease (NAFLD) has lately been proposed as a multisystem disease. Background, pre-proliferative retinopathy, and Proliferative Diabetic Retinopathy (PDR) with neovascularization are the three stages of diabetic retinopathy. Background DR describes the early stage of the disease, when chronic hyperglycemia damages the retinal vasculature, weakening the walls and causing microaneurysms. It can rupture and cause retinal haemorrhages as the illness develops to the pre-proliferative stage. Fluid deposition under the macula can be caused by a breakdown of the blood–retinal barrier and leakage of fluid and proteins into the retina via compromised microvasculature, compromising central vision. This causes maculopathy and macular edoema, which are the most common causes of visual loss in people with DR at any stage. Occlusion and degeneration of capillaries occur as a result of gradual retinal hypoperfusion leading to ischemia and loss of vascular integrity. Hypoxia is produced, which promotes the expression of proangiogenic growth factors like VEGF. This causes aberrant new vascular formation in the retina, which leads to the advancement of proliferative DR. Because these new arteries are fragile and disordered, they may induce vitreous haemorrhage or traction on the retina. This could lead to retinal detachment in the long run. Both of these disorders have the potential to cause dramatic vision loss.

The mechanism by which hyperglycemia causes microvascular damage is unknown. A number of variables and metabolic processes have been identified as contributing to hyperglycemic microvascular injury. The polyol pathway, which metabolises glucose, is activated when intracellular sugar levels rise. Deposition of Advanced Glycation End Products (AGEs), activation of protein kinase C, and overexpression of AGE receptors and the hexokinase pathway result as a result of this. This produces an increase in intracellular reactive oxygen species, which leads to oxidative stress and irreversible cell damage. Hyperglycemia causes vasodilation and blood flow alterations due to hemodynamic changes.

Increased glucose levels have also been demonstrated to promote pericyte apoptosis, which has been linked to early stages of DR. Capillary occlusion and consequent ischemia, are caused by damage and death of pericytes and endothelial cells. Hypoxia-Inducible Factor 1 (HIF-1) is stimulated as a result, and VEGF, a crucial mediator of angiogenesis, is activated. Angiopoietins (Ang-1, Ang-2) are further pro-angiogenic factors that contribute to the pathogenesis of DR and have recently been identified as potential

Correspondence to: Gloria Simmons G, Editorial office, Journal of Medical Diagnostic Methods, Barcelona, Spain, E-mail: editor.jmdm@journalres.com

Received: August 06, 2021; **Accepted:** August 16, 2021; **Published:** August 31, 2021

Citation: Simmons G (2021) Recent Medical Advancements in Diabetic Retinal Disease Treatment. J Med Diagn Meth. 10:350.2021.10.350.

additional treatment targets. In addition, recent human and animal research has revealed that the Kallikrein-Kinin System (KKS) may have a role in retinal vascular permeability, vasodilation, and retinal thickening in DR. Chronic inflammation is caused by long-term hyperglycemia, oxidative stress, and other molecular mediators. The DR eyes exhibit higher amounts of proinflammatory cytokines such Tumour Necrosis Factor (TNF-), Interleukin 1 (IL-1), and IL-6, as well as chemokines like Monocyte Chemoattractant Protein 1 (MCP-1), CCL2, and CCL5. Intracellular adhesion molecules such as ICAM-1 and VCAM-1 are secreted by activated cytokines, which attract monocytes and leukocytes and enhance subsequent inflammatory reactions. Leukocytes interact with endothelial cells, causing a disruption of the blood–retinal barrier and the release of MMPs and angiogenic factors, all of which lead to neovascularization. Improved knowledge of the role of inflammation in the aetiology of DR has led to the identification of novel treatment targets that may have fewer side effects than corticosteroids.